Cigna Group (CI) is a "clear standout" in the volatile health-care insurance industry, thanks in part to a "diversified and stable earnings flow," Oppenheimer said Friday in a report.
"The company's service-based platform leaves minimal exposure to risk-products that are igniting volatility across the managed care space," Oppenheimer said.
Cigna's Evernorth division has been capitalizing on surging demand for GLP-1 medications to treat Type 2 diabetes and obesity, starting programs that cap out-of-pocket costs and streamline access, the report said.
Cigna "remains one of the most attractive stocks to own" with "an attractive portfolio that should yield solid growth," the report said.
Oppenheimer reiterated its outperform rating on Cigna stock and price target of $375.
Price: 314.71, Change: +0.31, Percent Change: +0.10
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。